Magnolia Regenerative Medicine Review
Appears to have shut downMagnolia Regenerative Medicine is closed and is not taking new patients. Its lowest price, $99 a month, was paid up front.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Magnolia Regenerative Medicine is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $99/mo. No longer offered.
See our top-rated GLP-1 providers →Magnolia Regenerative Medicine sold compounded semaglutide and tirzepatide with B12 by membership, beside hormone, recovery and anti-aging care. It has closed. In October 2026 its website no longer loaded: neither the plain nor the www version of its address resolved in DNS, on two checks hours apart.
Vetted alternatives to Magnolia Regenerative Medicine
Editorial score · methodology
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Found
Best for: people who want clinician visits billed to commercial insurance, with compounded medication in the plan price
Editorial score · methodology
Magnolia Regenerative Medicine at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $99/mo
- What it included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letters found
How Magnolia Regenerative Medicine scores
Magnolia Regenerative Medicine has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something Magnolia Regenerative Medicine published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
6.0/10$99/month is 50% below the $199 median for compounded semaglutide across the sellers we compare. Every listed price requires paying for several months up front, so Value is capped at 6.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
6.5/10No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Magnolia Regenerative Medicine
Last checked October 2026- Checked the listed price across 2 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Magnolia Regenerative Medicine
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Cancelling Magnolia Regenerative Medicine
Taken from the terms Magnolia Regenerative Medicine publishes. Terms change, so check the current policy before you subscribe.
- Cancel any time
- Yes
- Minimum commitment
- Membership auto-renews monthly until canceled
- Refund policy
- "THERE ARE NO REFUNDS ON MEDICATIONS"
Medications Magnolia Regenerative Medicine listed
Magnolia Regenerative Medicine listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
Weight-loss page: "SEMAGLUTIDE+B12 — from $99/mo. Injection · Monthly & quarterly options available".
Weight-loss page: "TIRZEPATIDE+B12 — from $179/mo. Injection · Monthly & quarterly options available".
In its favor
- Semaglutide cost $99 a month, 50% below the $199 median for compounded semaglutide across the sellers we compare
- Tirzepatide cost $179 a month, 33% below the $269 median for compounded tirzepatide across the sellers we compare
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
- The monthly price stayed the same as the dose went up
- The monthly price included the medication, clinician visits and shipping
- We found no FDA warning letters issued to Magnolia Regenerative Medicine
Against it
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Magnolia Regenerative Medicine is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What Magnolia Regenerative Medicine charged
Magnolia Regenerative Medicine charged $99/month, and held that rate across every dose.
- Compounded semaglutide: $99/month
- Compounded tirzepatide: $179/month
For compounded semaglutide, the median across the sellers we compare is $199/month, so Magnolia Regenerative Medicine's $99 is genuinely below the middle, not just advertised that way.
AgelessRx, at about $99/month, is the closest like-for-like alternative we review.
What Magnolia Regenerative Medicine dispensed
Magnolia Regenerative Medicine prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product: the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
Safety and disclosure
Magnolia Regenerative Medicine told buyers its price before the medical questionnaire. We found no FDA warning letters issued to Magnolia Regenerative Medicine. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
Magnolia Regenerative Medicine is no longer taking new patients, so the choice is among the sellers that are still open.
The Bottom Line
Magnolia Regenerative Medicine is closed and is not taking new patients. Its lowest price, $99 a month, was paid up front.
Where Magnolia Regenerative Medicine is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Found.
If none of these fits, our guide to alternatives to Magnolia Regenerative Medicine sets more sellers in the same category beside Magnolia Regenerative Medicine on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Magnolia Regenerative Medicine review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of October 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.